Circulating Her-2/Neu Extracellular Domain in Breast Cancer Patients-Correlation with Prognosis and Clinicopathological Parameters Including Steroid Receptor, Her-2/Neu Receptor Coexpression

Pathology and Oncology Research

Volumn 21, Issue 3, 2015, Pages 589-595

  Barić, Marina ^a   Kulić, Ana ^a   Sirotković Skerlev, Maja ^a   Dedić Plavetić, Natalija ^a   Vidović, Marina ^a   Horvatić Herceg, Gordana ^b   Vrbanec, Damir ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Breast cancer; HER 2 neu ECD; Prognosis; Steroid receptor HER 2 neu receptor coexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; STEROID RECEPTOR; ERBB2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR INVASION; BLOOD; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84939416055     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9859-6     Document Type: Article

References (29)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 4:320–368
3. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD et al (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36:1127–1134
4. Zeng S, Yang Y, Tan Y, Lu C, Pan Y, Chen L et al (2012) ERBB2-induced inflammation in lung carcinogenesis. Mol Biol Rep 39:7911–7917
5. Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M et al (2010) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16:1553–1560
6. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 21:283–290
7. Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G (2012) HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65:237–241
8. Tsé C, Gauchez AS, Jacot W, Lamy PJ (2012) HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 38:133–142
9. Sasso M, Bianchi F, Ciravolo V, Tagliabue E, Campiglio M (2011) HER2 splice variants and their relevance in breast cancer. J Nucleic Acids Investig 2:e9
10. Horwitz KB, Mcguire WL (1977) Progesterone and progesterone receptors in experimental breast cancer. Cancer Res 37:1733–1738
11. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359–377
12. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP (2003) Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49:1579–1598
13. Dresse M MD, Heinemann V, Kahlert S, Bauerfeind I, Nagel D, et al. (2009) HER-2/neu in tissue and serum at time of primary breast cancer. J Clin Oncol Abstract #11500.
14. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY et al (2009) Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 27:1694–1705
15. Carney WP, Bernhardt D, Jasani B (2013) Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer 5:31–39
16. Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G (2007) Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res 125:137–142
17. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A et al (2008) Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON 13:409–413
18. Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W et al (2005) Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res 25:1433–1440
19. Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF (2004) Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 19:14–22
20. Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J et al (2012) High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol 138:275–284
21. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749
22. Codony-Servat J, Albanell J, Lopez-Talavera J, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196–1201
23. Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT et al (2006) c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 92:311–317
24. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I et al (2008) Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 19:883–890
25. Ma L, Yang HY, Han XH, Li J, Wang F, Zhang CL et al (2012) Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. Chin Med J 125:4104–4110
26. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J et al (2010) Evaluation of tumor markers (HER-2/neuoncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 31:171–180
27. Duru N, Candas D, Jiang G, Li JJ (2014) Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol 140(1):1–14
28. Lee CY, Lin Y, Bratman SV, Feng W, Kuo AH, Scheeren FA et al (2014) Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 74(1):341–352
29. Samy N, Ragab HM, El Maksoud NA, Shaalan M (2010) Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark 6:63–72